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Adenosine receptors are G protein-coupled receptors and
are implicated in several neurological and psychiatric dis-
orders such as Parkinson's disease, schizophrenia and
Alzheimer's disease. These receptors can be distinguished
by their affinity for adenosine analogues and by their pre-
ferred signal transduction pathway. The A2A receptor has
an unusually long intracellular carboxyl terminus. We
identified SAP102 (synapse-associated protein of 102
kDa) as a novel interaction partner of the adenosine A2A
receptor. SAP102 belongs to the family of MAGUK (mem-
brane-associated guanylate kinase-like domain) proteins.
These proteins have an established function in synaptic
organization, which is reflected by their modular struc-
ture. Our data demonstrate that the A2A receptor binds to
C-terminal domains of SAP102. Furthermore we identi-
fied the responsible binding motif consisting of 5 amino
acids in the receptor's C-terminus. In hippocampal neu-
rons we observed a co-localization of both proteins espe-
cially in punctuate structures along the neurite extensions
that presumably represented dendritic spines. In the next
step we will use several fluorescence-based techniques in
order to investigate the influence of SAP102 on the mobil-
ity and targeting of the A2A receptor.
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